![](https://financialmodelingprep.com/image-stock/DMTK.png)
DermTech, Inc. (DMTK)
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
$3.29M
Dr. John D. Dobak M.D.
255.00
La Jolla, CA
Jun 20, 2017
-0.04
$-2.65
2.20
3.53
-572.19%
-0.04
-0.00
0.08
0.21
3.31
-87.04%
-138.79%
Similar stocks (5)
TransMedics Group, Inc.
TMDX
Fulgent Genetics, Inc.
FLGT
ClearPoint Neuro, Inc.
CLPT
CuriosityStream Inc.
CURI
Outset Medical, Inc.
OM
ETF Exposure (1)
Jacob Forward ETF
JFWD
1.22%
Similar stocks (5)
TransMedics Group, Inc.
TMDX
Fulgent Genetics, Inc.
FLGT
ClearPoint Neuro, Inc.
CLPT
CuriosityStream Inc.
CURI
Outset Medical, Inc.
OM
ETF Exposure (1)
Jacob Forward ETF
JFWD
1.22%